The Intrauterine Device: How to Deploy This Strategy in the Molecular World?

Summary

Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance.

See related article by Bowen et al., p. 5073